Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

As af Klint’s fame has grown, so have the questions—about what she believed, whom she worked with, and who should be allowed ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

The 9 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 5.7%. In ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...